ALX Oncology (NASDAQ:ALXO) Price Target Cut to $1.50 by Analysts at Stifel Nicolaus

ALX Oncology (NASDAQ:ALXO) had its price target decreased by stock analysts at Stifel Nicolaus from $3.00 to $1.50 in a report released on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 39.53% from the company’s current price.

Several other equities research analysts also recently commented on ALXO. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of ALX Oncology in a report on Friday. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $3.00 in a report on Thursday. Piper Sandler lifted their price objective on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday. Finally, UBS Group decreased their target price on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and an average price target of $4.14.

ALX Oncology Stock Down 17.9 %

Shares of ALXO stock traded down $0.24 on Friday, reaching $1.08. 1,953,193 shares of the company were exchanged, compared to its average volume of 969,938. ALX Oncology has a one year low of $0.95 and a one year high of $17.83. The company has a market cap of $56.70 million, a price-to-earnings ratio of -0.36 and a beta of 1.01. The company has a 50-day moving average of $1.40 and a 200-day moving average of $1.63. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82.

Institutional Trading of ALX Oncology

Institutional investors have recently made changes to their positions in the company. Almitas Capital LLC purchased a new position in ALX Oncology during the fourth quarter worth about $2,042,000. Bank of America Corp DE lifted its position in shares of ALX Oncology by 492.9% during the 4th quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock worth $1,729,000 after buying an additional 860,703 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of ALX Oncology in the 4th quarter worth approximately $1,380,000. Two Sigma Advisers LP grew its holdings in shares of ALX Oncology by 64.6% in the fourth quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock valued at $1,376,000 after acquiring an additional 323,400 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in ALX Oncology by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 740,106 shares of the company’s stock worth $1,236,000 after acquiring an additional 39,259 shares during the period. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.